Document is current
Any future updates will be listed below
-
Authors
Buchbinder, Elizabeth I. https://orcid.org/0000-0002-7979-8953
Dutcher, Janice P.
Daniels, Gregory A.
Curti, Brendan D.
Patel, Sapna P.
Holtan, Shernan G.
Miletello, Gerald P.
Fishman, Mayer N.
Gonzalez, Rene
Clark, Joseph I.
Richart, John M.
Lao, Christopher D.
Tykodi, Scott S.
Silk, Ann W.
McDermott, David F.
-
Funding
Funding for this research was provided by:
Prometheus (Not applicable)
-
More Information
Article History
Received: 31 October 2018
Accepted: 31 January 2019
First Online: 18 February 2019
Ethics approval and consent to participate
: The study was approved by the institutional review boards of the sites enrolling subjects and all patients provided written, informed consent.
: Not applicable.
: EB receives clinical trial support from BMS and Merck, JD receives consulting income from Prometheus, BMS, Tracon, Iovance, Eisai, Merck, and Amgen, SH receives consulting income from Incyte, AS receives clinical trial support from BMS and Merck and receives consulting income from Merck. JC receives consulting income from BMS and Merck. ST receives clinical trial support from Peloton Therapeutics, Merck, Nektar Therapeutics, Calithera Biosciences, Jounce Therapeutics Pfizer, Genentech, ARGOS Therapeutics and BMS, he also receives consulting honoraria from Calithera Biosciences, Prometheus Laboratories and Bristol-Myers Squibb. GD, BC, SP, SH, GM, MF, RG, JC, JR, CL ST, AS and DM all receive institutional research funding from Prometheus. DM receives consulting honoraria from BMS, Pfizer, Merck, Novartis, Eisai, Exelixis, Array, Genentech and Jounce.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
